Why Codiak BioSciences Shares Are Falling During Tuesday's Session

What Else?

Codiak intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock and warrants to purchase shares of common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions.

All the securities to be sold in the proposed offering will be sold by Codiak. The offering is subject to market and other conditions, and Codiak BioSciences says there can be no assurances as to whether or when the offering may be completed.

See Also: Why Akari Therapeutics Shares Are Getting Obliterated

According to data from Benzinga Pro, Codiak BioSciences has a 52-week high of $19.99 and a 52-week low of $1.14.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.